Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1370142 | Bioorganic & Medicinal Chemistry Letters | 2011 | 6 Pages |
Abstract
The JAK2/STAT pathway has important roles in hematopoiesis. With the discovery of the JAK2 V617F mutation and its presence in many patients with myeloproliferative neoplasms, research in the JAK2 inhibitor arena has dramatically increased. We report a novel series of potent JAK2 inhibitors containing a 2,7-pyrrolotriazine core. To minimize potential drug-induced toxicity, targets were analyzed for the ability to form a glutathione adduct. Glutathione adduct formation was decreased by modification of the aniline substituent at C2.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Linda R. Weinberg, Mark S. Albom, Thelma S. Angeles, Henry J. Breslin, Diane E. Gingrich, Zeqi Huang, Joseph G. Lisko, Jennifer L. Mason, Karen L. Milkiewicz, Tho V. Thieu, Ted L. Underiner, Gregory J. Wells, Kevin J. Wells-Knecht, Bruce D. Dorsey,